Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
  1. Home
  2. Search

Refine search

Refine search

Access:
Content type:
Publication date:
Apply   From and To filters
Subject: Show more
Journals Show more
Publishers: Show more
Societies Show more
Series: Show more
Collections: Show more

Actions for selected content:

Select all | Deselect all
  • View selected items
  • Export citations
  • Download PDF (zip)
  • Save to Kindle
  • Save to Dropbox
  • Save to Google Drive

Save Search

You can save your searches here and later view and run them again in "My saved searches".

Please provide a title, maximum of 40 characters.
Cancel
×

1 results

  • 4 - Predictive biology of ovarian cancer

  • from SECTION 1 - BIOLOGY OF GYNAECOLOGICAL CANCERS: OUR CURRENT UNDERSTANDING
  • Edited by Sean Kehoe, Richard J. Edmondson, Martin Gore, Iain A. McNeish
  • Book:
    Gynaecological Cancers
    Published online:
    05 February 2014
    Print publication:
    01 June 2011, pp 41-54

  • Summary

    This chapter concentrates on recent robust advances that are likely to affect clinical care over the short to medium term. It discusses potential biomarkers for stratified treatment of high-grade serous (HGSOC) and their relationship with platinum sensitivity and resistance. The accurate diagnosis of sub-type before chemotherapy treatment is vital as it provides strong prognostic and biological information. Many expression microarray studies have attempted to define prognostic and predictive signatures for chemoresistance in epithelial ovarian cancer (EOC). DNA copy number analysis has also been investigated as a predictive marker. Ultrasound- or computed tomography (CT)-guided biopsy is the standard of care for initial diagnosis of women with suspected ovarian cancer. Intratumoral genetic heterogeneity in HGSOC has been demonstrated both within a region of tumour and between different metastatic sites. These genetic differences could be expected to alter chemosensitivity.